153 related articles for article (PubMed ID: 12127526)
1. Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185(erbB)) tyrosine kinases.
Sun L; Cui J; Liang C; Zhou Y; Nematalla A; Wang X; Chen H; Tang C; Wei J
Bioorg Med Chem Lett; 2002 Aug; 12(16):2153-7. PubMed ID: 12127526
[TBL] [Abstract][Full Text] [Related]
2. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
4. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
5. 7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.
Widler L; Green J; Missbach M; Susa M; Altmann E
Bioorg Med Chem Lett; 2001 Mar; 11(6):849-52. PubMed ID: 11277535
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor.
Fry DW; Nelson JM; Slintak V; Keller PR; Rewcastle GW; Denny WA; Zhou H; Bridges AJ
Biochem Pharmacol; 1997 Oct; 54(8):877-87. PubMed ID: 9354588
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C
J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163
[TBL] [Abstract][Full Text] [Related]
8. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
[TBL] [Abstract][Full Text] [Related]
9. Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.
Gaul MD; Guo Y; Affleck K; Cockerill GS; Gilmer TM; Griffin RJ; Guntrip S; Keith BR; Knight WB; Mullin RJ; Murray DM; Rusnak DW; Smith K; Tadepalli S; Wood ER; Lackey K
Bioorg Med Chem Lett; 2003 Feb; 13(4):637-40. PubMed ID: 12639547
[TBL] [Abstract][Full Text] [Related]
10. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.
Lackey KE
Curr Top Med Chem; 2006; 6(5):435-60. PubMed ID: 16719802
[TBL] [Abstract][Full Text] [Related]
11. 2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2.
Boyd HF; Flynn ST; Hickey DM; Ife RJ; Jones M; Leach CA; Macphee CH; Milliner KJ; Rawlings DA; Slingsby BP; Smith SA; Stansfield IG; Tew DG; Theobald CJ
Bioorg Med Chem Lett; 2000 Feb; 10(4):395-8. PubMed ID: 10714508
[TBL] [Abstract][Full Text] [Related]
12. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).
Discafani CM; Carroll ML; Floyd MB; Hollander IJ; Husain Z; Johnson BD; Kitchen D; May MK; Malo MS; Minnick AA; Nilakantan R; Shen R; Wang YF; Wissner A; Greenberger LM
Biochem Pharmacol; 1999 Apr; 57(8):917-25. PubMed ID: 10086326
[TBL] [Abstract][Full Text] [Related]
13. 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors.
Wissner A; Berger DM; Boschelli DH; Floyd MB; Greenberger LM; Gruber BC; Johnson BD; Mamuya N; Nilakantan R; Reich MF; Shen R; Tsou HR; Upeslacis E; Wang YF; Wu B; Ye F; Zhang N
J Med Chem; 2000 Aug; 43(17):3244-56. PubMed ID: 10966743
[TBL] [Abstract][Full Text] [Related]
14. Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents.
Vu CB; Luke GP; Kawahata N; Shakespeare WC; Wang Y; Sundaramoorthi R; Metcalf CA; Keenan TP; Pradeepan S; Corpuz E; Merry T; Bohacek RS; Dalgarno DC; Narula SS; van Schravendijk MR; Ram MK; Adams S; Liou S; Keats JA; Violette SM; Guan W; Weigele M; Sawyer TK
Bioorg Med Chem Lett; 2003 Sep; 13(18):3071-4. PubMed ID: 12941336
[TBL] [Abstract][Full Text] [Related]
15. The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases.
Denny WA
Farmaco; 2001; 56(1-2):51-6. PubMed ID: 11347967
[TBL] [Abstract][Full Text] [Related]
16. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
18. p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones.
Natarajan SR; Wisnoski DD; Thompson JE; O'Neill EA; O'Keefe SJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4400-4. PubMed ID: 16750629
[TBL] [Abstract][Full Text] [Related]
19. Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC.
Rose Y; Ciblat S; Reddy R; Belley AC; Dietrich E; Lehoux D; McKay GA; Poirier H; Far AR; Delorme D
Bioorg Med Chem Lett; 2006 Feb; 16(4):891-6. PubMed ID: 16298129
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor signaling cascade as target for tyrphostin (RG 50864) in epithelial cells. Paradoxical effects on mitogen-activated protein kinase kinase and mitogen-activated protein kinase activities.
Nowak F; Jacquemin-Sablon A; Pierre J
Biochem Pharmacol; 1997 Feb; 53(3):287-98. PubMed ID: 9065732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
